Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

Ähnliche Einträge

• Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
  Veröffentlicht: (2010)
• A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
  Veröffentlicht: (2005)
• An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial
  Veröffentlicht: (2007)
• Predicting major bleeding in patients with noncardioembolic stroke on antiplatelets: S2TOP-BLEED
  von: Hilkens, Nina A., et al.
  Veröffentlicht: (2017)
• Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial
  Veröffentlicht: (2010)